Innovative Alzheimer’s Clinical Trials Using Personalized Neuromodulation
Maybe the way we have been trying to treat Alzheimer’s disease has been all wrong? Ken Mariash, the CEO at Synaptica Therapeutics, thinks so. And the lack of compelling treatments thus far, confirms it. For decades the focal point of treating Alzheimer’s, a disease that affects millions worldwide, has been the reduction of amyloid plaque. … Read more